You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 1372 TriTCE Co-Stim: a novel trispecific T cell engager platform, with integrated CD28 costimulation, engineered to widen the therapeutic window for treatment of poorly infiltrated tumors

Citation Tools

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Novel Single-Agent Immunotherapies
1372 TriTCE Co-Stim: a novel trispecific T cell engager platform, with integrated CD28 costimulation, engineered to widen the therapeutic window for treatment of poorly infiltrated tumors

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Newhook L, Bhojane P, Repenning P, et al
1372 TriTCE Co-Stim: a novel trispecific T cell engager platform, with integrated CD28 costimulation, engineered to widen the therapeutic window for treatment of poorly infiltrated tumors
Journal for ImmunoTherapy of Cancer 2023;11:doi: 10.1136/jitc-2023-SITC2023.1372